Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. MedImmune was originally incorporated in June 1987, under the name Molecular Vaccines Inc and commenced operations in April 1988. In October 1990, the company changed its name to MedImmune Inc and is now a biotechnology company with five products on the market (Ethyol, NeuTrexin, Synagis, CytoGam and RespiGam) and a diverse product pipeline. The company is focused on using advances in immunology and other biological sciences to develop new products that address significantly unmet medical needs in areas of infectious disease and immune regulation. The company also focuses on oncology through its wholly-owned subsidiary, MedImmune Oncology Inc.